What berberine side effects show up most often?

Berberine is sold as a “natural” answer to blood sugar, appetite, and weight. The question most people actually want answered is simpler: what happens when you take it? A 2026 JAMA Network Open randomized clinical trial led by Jingkuo Li put adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) on 1 g/day for six months. That trial offers one of the clearest recent windows into side effects in a real clinical setting. Berberine was generally tolerated. But the complaints that kept surfacing were, overwhelmingly, gastrointestinal.

That framing matters because berberine is now sold into a market saturated with “natural Ozempic” talk. Safety questions tend to get flattened into two extremes: either a supplement is harmless because it’s plant-derived, or it’s dangerous because a trial table records any adverse event at all. The evidence sits between those poles. An overview of systematic reviews in BMC Complementary Medicine and Therapies points to a mostly mild, gut-centered side-effect profile across the literature. The National Center for Complementary and Integrative Health describes the reported adverse effects as “primarily gastrointestinal symptoms such as nausea, abdominal pain, bloating, constipation, or diarrhea.” For most readers, the answer is straightforward: berberine’s first safety problem is usually stomach trouble. Its more serious caution is the possibility of drug interactions.

What the 2026 trial actually found

Li and colleagues randomized 337 participants — far more useful than the tiny studies supplement marketing tends to cite. The berberine group took 1 g/day. Treatment lasted six months. Serious adverse events: 3.6 percent in the berberine group versus 1.2 percent on placebo. Nonserious adverse events of interest: 10.1 percent versus 7.7 percent.

The numbers themselves do not make berberine a high-risk supplement, and they do not prove that every event in the berberine arm was caused by berberine. What they do show is that “well tolerated” is not the same as “side-effect free.” In Li’s trial, how well people tolerated the compound looked acceptable at the group level, but adverse events still happened and still deserve plain-language reporting. That distinction matters for anyone trying to decide whether the supplement sounds merely annoying — it may cause gut discomfort — or meaningfully risky — it may not fit with their medications or medical history.

The dose question deserves the same scrutiny. A 1 g/day figure is a study condition, not a self-start recommendation. Anyone considering berberine for blood sugar, lipids, or weight should treat the dose in a paper as research context, not shopping advice, and consult a clinician before starting.

Why stomach symptoms show up first

What makes berberine’s side-effect story notable is partly how ordinary it is. This is not mainly about dramatic emergency signals. It is about whether people feel well enough to keep taking the compound. The NCCIH summary lists nausea, abdominal pain, bloating, constipation, and diarrhea — the kind of symptoms that sound minor in a results table but become decisive in daily life. When a supplement repeatedly causes cramping, loose stools, or constipation, most people will stop long before a clinician ever has to interpret a lab value.

Review-level evidence points the same way. The BMC overview of systematic reviews does not argue that berberine is universally unsafe. It makes clear that most of the burden lands in the gut, and how well someone tolerates the compound has to be judged accordingly. That separates berberine from the clean marketing around many “metabolic” products. A compound can have a biologically active effect and still be limited by plain gastrointestinal friction.

Search demand tells its own story. Benefits are easy to advertise. Mild adverse effects are harder to fit into a before-and-after post. Readers end up sorting through anecdotes. The better approach is to ask what repeated, named patterns show up across trials — and here, the repeated pattern is not mysterious. GI upset comes first. Then a more careful discussion about who should be taking the compound at all.

Where the real caution is

Gut symptoms are the common nuisance. Drug interactions are the bigger reason not to treat berberine as an automatic add-on. NCCIH highlights interactions as a meaningful caution. This is relevant because the people most interested in berberine are often the same people already managing blood sugar, liver health, cholesterol, or weight with other interventions. A supplement can look manageable in a trial and still be a bad fit in a medicine cabinet that is already crowded.

“Natural Ozempic” is more misleading than useful for the same reason. It implies a simple substitute. The actual safety question is not whether berberine sounds similar to a popular drug in a social clip. It is whether a specific person can take it without setting off stomach problems, conflicting with existing treatment, or delaying better-supported care. A tolerability table cannot answer that on its own. It can only show that the side effects most often reported in research are mild enough to describe plainly and common enough to take seriously.

The evidence has ceilings too. The JAMA trial is helpful — randomized, six months — but it does not settle every long-term safety question or every interaction scenario. Review literature is useful for spotting patterns, but reviews are only as strong as the underlying trials. Skepticism toward definitive supplement claims makes sense here. An absence of dramatic safety signals is not proof that every use case has been mapped.

What to watch next

Future berberine safety studies worth watching will report adverse events in more detail, follow people for longer, and clarify what happens when the compound is used alongside common prescription therapies. Until those studies arrive, the most evidence-based answer to “what side effects should I expect?” remains grounded: in trials and reviews, berberine’s side effects are usually gastrointestinal, not sensational — but that does not make the supplement casual.

For readers tempted by the marketing: berberine may be promising in some metabolic settings. It may also make some people feel bad quickly, and it should not be layered onto existing treatment without medical advice. The boring safety questions turn out to be the important ones.

References

1. Li J, Zhang H, et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. JAMA Network Open. 2026. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2844037
2. Berberine and health outcomes: an overview of systematic reviews. BMC Complement Med Ther. https://pmc.ncbi.nlm.nih.gov/articles/PMC12016319/
3. National Center for Complementary and Integrative Health. Berberine and Weight Loss: What You Need To Know. NCCIH. https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know